Skip to main content

Advertisement

SpringerLink
Log in

Ischemic Heart Disease: Special Considerations in Cardio-Oncology

  • Cardio-oncology (M Fradley, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease. In this sense, the presence of cancer and cancer-related comorbidities (e.g., thrombocytopenia, propensity to bleed, thrombotic status) substantially complicates the management of cardiovascular diseases in cancer patients. In this review, we will summarize the current state of knowledge on the management strategies for ischemic disease in patients with cancer, focusing on the challenges encountered when addressing these complexities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.

    Article  PubMed  Google Scholar 

  2. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular health of patients with cancer and cancer survivors: aroadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739–46.

    Article  PubMed  PubMed Central  Google Scholar 

  3. • Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? Journal of cancer survivorship: research and practice. 2013;7(2):253–61. We consider the paper of Weaver, et al. important as is one of the early articles published on CVDriskfactorsin cancerssurvivors, which might be overlooked and may compromiselong-termhealth and well-being.

    Article  Google Scholar 

  4. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107(7):2912–9.

    Article  CAS  PubMed  Google Scholar 

  5. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740.

    PubMed  PubMed Central  Google Scholar 

  7. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–32.

    PubMed  Google Scholar 

  8. Herrmann J, Lerman A. An update on cardio-oncology. Trends in cardiovascular medicine. 2014;24(7):285–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004;110(3):278–84.

    Article  PubMed  Google Scholar 

  10. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  CAS  PubMed  Google Scholar 

  11. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–31.

    Article  PubMed  Google Scholar 

  12. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2016;87(5):E202–23.

    Article  Google Scholar 

  13. Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348–51.

    Article  CAS  PubMed  Google Scholar 

  14. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303–7.

    Article  CAS  PubMed  Google Scholar 

  15. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302.

    Article  CAS  PubMed  Google Scholar 

  16. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Annals of oncology: official journal of the European Society for Medical Oncology. 2002;13(3):484–5.

    Article  CAS  Google Scholar 

  17. de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10(11):1795–801.

    Article  Google Scholar 

  18. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother. 1994;28(3):374–8.

    Article  CAS  PubMed  Google Scholar 

  19. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients. Medical science monitor: international medical journal of experimental and clinical research. 2002;8(6):PI51–7.

    CAS  Google Scholar 

  20. Freeman NJ, Costanza ME. 5-fluorouracil-associated cardiotoxicity. Cancer. 1988;61(1):36–45.

    Article  CAS  PubMed  Google Scholar 

  21. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9(9):1704–12.

    Article  CAS  Google Scholar 

  22. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.

    Article  CAS  PubMed  Google Scholar 

  23. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610–1.

    Article  PubMed  Google Scholar 

  24. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clinical lymphoma, myeloma & leukemia. 2012;12(5):337–40.

    Article  CAS  Google Scholar 

  25. Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552–6.

    Article  CAS  PubMed  Google Scholar 

  26. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9.

    Article  PubMed  Google Scholar 

  27. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.

    Article  CAS  PubMed  Google Scholar 

  28. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287–97.

    Article  CAS  PubMed  Google Scholar 

  29. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer. 2008;112(7):1522–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.

    Article  CAS  PubMed  Google Scholar 

  31. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98(5):1614–5.

    Article  CAS  PubMed  Google Scholar 

  32. Kastritis E, Dimopoulos M. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Leukemia & lymphoma. 2007;48(12):2295–7.

    Article  Google Scholar 

  33. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(16):3718–25.

    Article  CAS  Google Scholar 

  34. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015;116(3):358–65.

    Article  CAS  PubMed  Google Scholar 

  35. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866–73.

    Article  CAS  PubMed  Google Scholar 

  36. Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656–65.

    Article  PubMed  PubMed Central  Google Scholar 

  37. • DarbySC, EwertzM, McGaleP, BennetAM, Blom-GoldmanU, BronnumD, et al.Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England journal of medicine.2013;368(11):987–998. We consider this paper important because provides new insights on the cardiotoxic effect of radiotherapy that can lead to significant cardiac complications, affecting the overall survival in these patients.

  38. Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J. 1993;69(6):496–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys. 2002;29(10):2391–403.

    Article  PubMed  Google Scholar 

  40. Krone RJ. Managing coronary artery disease in the cancer patient. Prog Cardiovasc Dis. 2010;53(2):149–56.

    Article  PubMed  Google Scholar 

  41. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):43–9.

    Article  Google Scholar 

  42. Chandra S, Lenihan DJ, Wei W, Yusuf SW, Tong AT. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J. 2009;36(3):205–13.

    PubMed  PubMed Central  Google Scholar 

  43. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.

    Article  CAS  PubMed  Google Scholar 

  44. Patel B, Kloner RA, Ensley J, Al-Sarraf M, Kish J, Wynne J. 5-fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. The American journal of the medical sciences. 1987;294(4):238–43.

    Article  CAS  PubMed  Google Scholar 

  45. Burgdorf C, Nef HM, Haghi D, Kurowski V, Radke PW. Tako-tsubo (stress-induced) cardiomyopathy and cancer. Ann Intern Med. 2010;152(12):830–1.

    Article  PubMed  Google Scholar 

  46. Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G, et al. 5-fluorouracil-induced Tako-tsubo-like syndrome. Pharmacotherapy. 2011;31(2):226.

    Article  PubMed  Google Scholar 

  47. Baumann S, Huseynov A, Goranova D, Faust M, Behnes M, Nolte F, et al. Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncology research and treatment. 2014;37(9):487–90.

    Article  PubMed  Google Scholar 

  48. Numico G, Sicuro M, Silvestris N, Mozzicafreddo A, Trogu A, Malossi A, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):e218–20.

    Article  Google Scholar 

  49. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155(3):408–17.

    Article  PubMed  Google Scholar 

  50. Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109(3):621–7.

    Article  CAS  PubMed  Google Scholar 

  51. Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J. 2010;37(3):336–40.

    PubMed  PubMed Central  Google Scholar 

  52. Endorsed by the Latin American Society of Interventional C, Pci Writing C, Levine GN, Bates ER, Blankenship JC, Bailey SR, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Society for Cardiovascular Angiography and Interventions. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2016;87(6):1001–19.

    Article  Google Scholar 

  53. Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443–50.

    Article  PubMed  Google Scholar 

  54. Nathan S, Rao SV. Radial versus femoral access for percutaneous coronary intervention: implications for vascular complications and bleeding. Current cardiology reports. 2012;14(4):502–9.

    Article  PubMed  Google Scholar 

  55. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012a;367(11):991–1001.

    Article  CAS  PubMed  Google Scholar 

  56. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012b;367(11):991–1001.

    Article  CAS  PubMed  Google Scholar 

  57. Nascimento BR, Belfort AF, Macedo FA, Sant’Anna FM, Pereira GT, Costa MA, et al. Meta-analysis of deferral versus performance of coronary intervention based on coronary pressure-derived fractional flow reserve. Am J Cardiol. 2015;115(3):385–91.

    Article  PubMed  Google Scholar 

  58. Mintz GS, Pichard AD, Kovach JA, Kent KM, Satler LF, Javier SP, et al. Impact of preintervention intravascular ultrasound imaging on transcatheter treatment strategies in coronary artery disease. Am J Cardiol. 1994;73(7):423–30.

    Article  CAS  PubMed  Google Scholar 

  59. Jang JS, Song YJ, Kang W, Jin HY, Seo JS, Yang TH, et al. Intravascular ultrasound-guided implantation of drug-eluting stents to improve outcome: a meta-analysis. JACC Cardiovascular interventions. 2014;7(3):233–43.

    Article  PubMed  Google Scholar 

  60. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group. N Engl J Med. 1999;341(26):1949–56.

    Article  CAS  PubMed  Google Scholar 

  61. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519–21.

    Article  CAS  PubMed  Google Scholar 

  62. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009–19.

    Article  CAS  PubMed  Google Scholar 

  63. Ko DT, Chiu M, Guo H, Austin PC, Goeree R, Cohen E, et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol. 2009;53(19):1773–82.

    Article  PubMed  Google Scholar 

  64. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003;72(1):43–52.

    Article  PubMed  Google Scholar 

  65. Brown ML, Schaff HV, Sundt TM. Conduit choice for coronary artery bypass grafting after mediastinal radiation. J Thorac Cardiovasc Surg. 2008;136(5):1167–71.

    Article  PubMed  Google Scholar 

  66. Gansera B, Schmidtler F, Angelis I, Botzenhardt F, Schuster T, Kiask T, et al. Quality of internal thoracic artery grafts after mediastinal irradiation. Ann Thorac Surg. 2007;84(5):1479–84.

    Article  PubMed  Google Scholar 

  67. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. The Canadian journal of cardiology. 2006;22(3):251–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, et al. 5-fluorouracil induces arterial vasocontractions. Annals of oncology: official journal of the European Society for Medical Oncology. 2004;15(4):661–4.

    Article  CAS  Google Scholar 

  69. Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;15:117–30.

    Google Scholar 

  70. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273–9.

    Article  CAS  PubMed  Google Scholar 

  71. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA

    Dana Elena Giza MD, Juan Lopez-Mattei MD, Gloria Iliescu MD, Kaveh Karimzad MD, Peter Kim MD & Cezar Iliescu MD

  2. Odessa Heart Institute,Department of Internal Medicine, Permian Research Foundation, Texas-Tech University, Odessa, TX, 79761, USA

    Fernando Boccalandro MD

Authors
  1. Dana Elena Giza MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando Boccalandro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Lopez-Mattei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gloria Iliescu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaveh Karimzad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cezar Iliescu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cezar Iliescu MD.

Ethics declarations

Conflict of Interest

Dana Elena Giza, Fernando Boccalandro, Juan Lopez-Mattei, Gloria Iliescu, Kaveh Karimzad, and Cezar Iliescu each declare no potential conflicts of interest. Peter Kim is a consultant for Boehringer Ingelheim.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giza, D.E., Boccalandro, F., Lopez-Mattei, J. et al. Ischemic Heart Disease: Special Considerations in Cardio-Oncology. Curr Treat Options Cardio Med 19, 37 (2017). https://doi.org/10.1007/s11936-017-0535-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-017-0535-5

Keywords

Search

Navigation